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Abstract 
 Antimicrobial peptides (AMPs) have broad spectrum antimicrobial activity and are predominately 
short (11-100 amino acid), amphipathic, α-helical, and cationic peptides. AMPs are ubiquitous in nature 
but only a small number of natural AMPs have metal binding motifs involving the amino acid histidine. 
Examples are the Amino Terminal Copper and Nickel Binding Unit (ATCUN) and the HXXXH motif. 
The ATCUN motif is found in many natural AMPs and consists of an XXH motif at the N-terminus, 
while the HXXXH motif, coordinates Zn2+ ions when in an α-helical formation because the two histidines 
are positioned on the same face of the helix. Gaduscidin 1 (gad-1) is an AMP derived from Atlantic cod 
fish. Gad-1 is an α-helical peptide with 21 amino acids, five of which are histidine residues, and contains 
an ATCUN motif and an HXXXH motif. Herein, we investigate the role of histidine and metal binding in 
the antimicrobial activity of gad-1. We will present our current understanding of the mechanisms by 
which gad-1 induces bacterial cell death. Our data indicates that gad-1 targets the membrane based on β-
galactosidase and lipid peroxidation experiments. The activity of gad-1 is potentiated by the ATCUN 
motif, as the absence of the histidine in the third position lowers the activity against Escherichia coli 
eight-fold. The role of the HXXXH motif is unclear in gad-1, however despite the loss of the ATCUN 
motif, the peptide still retains some activity that could be potentiated by the HXXXH motif. The HXXXH 
motif is likely used as a second Cu2+ binding site, as gad-1 was shown to bind two Cu2+ ions using mass 
spectrometry. Based on lipid peroxidation experiments it is possible that this binding site, along with the 
ATCUN binding site, can produce ROS and peroxidize lipids giving gad-1 a multi-hit mode of action.  
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CHAPTER 1 
Introduction to antibiotic resistance and antimicrobial peptides 
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1.1 Mechanisms of antibiotic resistance 
In the United States, more than 23,000 people will die annually as a result of drug-resistant 
bacterial infections.1 The increase in drug-resistant pathogens is attributed to usage of antibiotics (ABXs) 
in the agricultural and livestock industry coupled with nosocomial infections, inadequate diagnoses, 
pressure by doctors to prescribe ABXs for viruses, and unfinished ABX doses by patients. Over 50% of 
prescribed ABXs are not necessary nor optimal treatments, leading to the need for more ABXs to be 
used.1 Many drug companies want to develop more profitable drugs than ABXs, which may be why the 
number of new ABXs have waned since the 1980’s, decreasing by more than 75% from 1980-1984 
compared to 2010-2014.2 New treatment alternatives are desperately needed as the number of new cases 
of ABX resistant superbugs increase annually.2 Options such as antimicrobial peptides (AMPs) can be 
used as novel antimicrobial agents against drug-resistant pathogens.  
The rise in resistance has been correlated with increased ABX usage.3 From 2000 to 2015 there 
was a 39% increase in ABX consumption worldwide that caused an escalation in the number of resistant 
pathogens.3  In 2011, there were a total of 2,049,442 drug-resistant cases reported with the main problems 
being methicillin resistant Staphylococcus aureus (MRSA), Streptococcus pneumoniae, nontyphoidal 
Salmonella spp., Neisseria gonorrhoeae, and Campylobacter spp.1 Other troubling pathogens were 
defined by The World Health Organization (WHO) as the ESKAPE pathogens, which are comprised of 
Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, 
Pseudomonas aeruginosa, and Enterobacter spp.4  The concern surrounding these ESKAPE species are 
that they commonly cause nosocomial infections and are acquired mainly by patients whose immune 
systems are already compromised.4 As an example of how quickly resistance can spread, the mcr-1 
plasmid, which yields resistance to colistin (polymyxin E), a last line ABX, was discovered in 
Escherichia coli in China5 and another E. coli strain in the US was found shortly after with the same 
plasmid.6  The E.coli isolate had a total of 15 ABX resistance genes and was either resistant or susceptible 
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to the most frequently used ABXs.6 ABX resistance is a major concern and is becoming a worldwide 
issue that needs to be addressed with more research into new ABX alternatives.  
Novel compounds with pathogen targets that do not easily mutate or confer resistance are greatly 
needed. The three main targets of traditional ABXs are inhibition of cell wall synthesis, nucleic acid 
synthesis, and protein synthesis. Due to the specific targets of ABXs, a pathogen can acquire a multitude 
of strategies to develop resistance to specific ABXs or can potentially gain multi-drug resistance (MDR) 
mechanisms. A pathogen can mutate an allosteric or active site to inhibit binding of an ABX, can acquire 
plasmids with multiple resistance genes, have mobile transposable chromosomal elements, or can produce 
inhibitory enzymes to confer resistance (Figure 1).  Efflux pumps, which push ABXs out of the cell, can 
be specific for one type of ABX or can export multiple ABX classes and contribute to MDR.7 Plasmids 
are easily acquirable from other bacteria via horizontal gene transfer, causing rapid spread of resistance in 
a population.8,9 Pathogens can also acquire broad spectrum resistance by altering their cell wall 
composition, although this may require too much energy to be advantageous for the cell.8,10  
 
 
Figure 1. Summary of methods that lead to ABX resistance  
 
 
 
Antibiotic Resistance Acquisition Methods 
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One example of an ABX class that inhibits cell wall synthesis are β-lactams. 9,11 This class targets 
the peptidoglycan cell wall synthesis in Gram-positive [G(+)] bacteria and to some extent in Gram-
negative [G(-)] bacteria by binding to the crosslinkers, [i.e. penicillin-binding proteins (PBPs)], that form 
a thick polymeric layer of sugar and amino acids (AAs) during peptidoglycan synthesis. 9,11  By binding 
the crosslinkers, β-lactams halt cell growth and weaken the cellular membrane. 9,11 Various examples of 
resistance have been demonstrated against β-lactams. One major mechanism driving resistance is the 
production of β-lactamases, enzymes that break down β-lactam ABXs.9 In G(-) bacteria, the β-lactamases 
can widen their active site to confer better activity against cephalosporin, a member of the β-lactams, but 
this alteration comes at the cost of also allowing other ABXs to be more active.9 A family of β-lactamases 
derived from natural cephalosporinases have proven to be a large problem with resistance in many 
pathogenic species but specifically with K. pneumoniae a member of the ESKAPE pathogens.9 
Carbapenems are one of last line ABXs for G(-) bacteria, because they are resistant to hydrolysis by most 
β-lactamases.9 Therefore, the acquisition of plasmids that produce carbapenemases, have compromised 
this last line ABX.9 The production of low affinity PBPs is another concerning mechanism of resistance.9 
A mobile chromosome named mec encodes PBP2a, a protein which contains a low affinity β-lactam 
binding site that is found in MRSA species and confers resistance to most known β-lactams without 
hindering the normal cell wall synthesis processes of the bacteria.9 The PBP genes can be recombined, as 
is the case with  Streptococcus spp. that have acquired resistance through mosaic genes.9   
Another class of ABX used as a last line of defense for G(-) infections are polymyxins, which are 
peptides that disrupt the cell membrane.10 Polymyxin B and colistin (polymyxin E) are cyclic, cationic 
peptides with fatty acid tails.12 Polymyxin B specifically binds to lipid A of lipopolysaccharide (LPS), a 
component of the cell membrane of G(-) bacteria, through electrostatic interactions and disrupts the 
membrane to cause cell death.10 The major resistance mechanism against polymyxins is the change in 
composition of LPS, more specifically the lipid A component of LPS.10  PmrAB-regulated genes can 
produce enzymes that add 4-aminoarabinose to the 4'-phosphate group on lipid A that decreases the net 
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charge of the LPS from -1.5 to 0.10 When there are missense mutations in either the A or B components, 
the resulting pmrC will be upregulated to alter lipid A by adding 4-aminoarabinose or 
phosphoethanolamine (PEtN).10 The addition of a PEtN moiety to the 1' and 4' phosphate groups will 
reduce the charge from -1.5 to -1.10 By making these charge modifications, the initial electrostatic 
interactions that allows the peptide ABX to bind to the LPS become limited and thereby reducing the 
efficacy of polymyxins.  
Although cell wall inhibitors are common, several classes of ABXs target intracellular 
components such as DNA and proteins. DNA gyrase and topoisomerase IV are both involved in strand 
breaks when DNA is replicating, the process of supercoiling DNA, and inhibiting DNA synthesis.13,24 
Quinolones or fluoroquinolones target these enzymes in G(-) and G(+) bacteria and include the ABXs 
ciprofloxacin, nalidixic acid, norfloxcacin, and ofloaxin.13 Quinolones work when two drug molecules 
intercalate into the cleaved or replicating DNA strand by binding to DNA gyrase and the DNA forming 
an ABX-enzyme-DNA complex to prevent DNA ligation.13 Permanent chromosomal breaks result and 
lead to an SOS response due to the DNA synthesis inhibition via the accumulation of reactive oxygen 
species (ROS) that can help mediate cell death.13,14  Resistance can occur when one or both of the 
enzymes are mutated, which has been demonstrated by multiple point mutations in gyrA and parC.9,13 An 
equally important mechanism of resistance is plasmid mediated, including Qnr proteins and [aac(6')-Ib-cr] 
that can decrease the binding events of DNA gyrase and DNA topoisomerase IV.9,13,14 This limits the 
number of cleavage sites the quinolones can intercalate into to provide protection from the ABX.9,13,14 In 
addition to this, increasing expression and acquisition of multiple efflux pumps can lead to resistance by 
pumping the quinolones out of the cell.9,13 
Two other ABXs that affect DNA synthesis and are threatened by drug-resistance are 
trimethaprim and sulfonamides, which both target folic acid metabolism.24 Sulfonamides specifically 
target and competitively inhibit the enzyme dihydropteroate synthase, which is involved in one of the last 
steps in the synthesis of folic acid.15 Sulfonamides are active against G(-) and G(+) organisms and are 
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selective because mammalian cells do not produce dihydropteroate synthase.15 ABX resistance to 
sulfonamides has been rapid due to the alteration of the enzyme active site by changing AAs in the 
sequence or by adding more AAs to change the tertiary structure.15 Resistance mediated gene transfer 
between species of the same bacteria, such as Neisseria meningiditis and N. gonorrheae, has also led to 
the rapid increase in resistance against sulfonamides.15 Trimethoprim is also a competitive inhibitor, but 
of dihydrofolate reductase in bacteria, and inhibits folic acid synthesis at a later point than sulfonamides, 
meaning that both drugs can be used synergystically.15 The most common cause of trimethoprim 
resistance is plasmid acquisition from other resistant bacteria.15  
The last of the three main targets that ABXs use to inhibit bacteria is inhibition of protein 
synthesis. Aminoglycosides target and bind the 30S ribosome, specifically bacterial ribosomes, as 
mammalian ribosomes are structurally different. 8,11 They target the aminoacyl (A-site) of the ribosomes, 
which is where the t-RNA binds first during protein synthesis.8 An rRNA methyltransferase, that can be 
plasmid acquired, can be expressed to methylate the A-site on the 16s rRNA inhibiting aminoglycosides 
binding.8 Mutations in the rrs gene and production of aminoglycosidase-modifying enzymes can lead to 
the inability of aminoglycosides to bind to 16s rRNA or mutate specific sites that inhibit binding.8 
Furthermore, multi-drug efflux pumps can be overexpressed to inhibit aminoglycoside efficiency, while 
porins can narrow, be downregulated, or stop being expressed, as they may be potentially responsible for 
transport into the cell.8 Similar to polymyxin, LPS modifications could confer resistance to G(-) bacteria 
because aminoglycosides are cationic.8  
In short, the mechanisms of ABX resistance includes plasmid acquisition, with multiple drug 
resistance cassettes, increasing expression of efflux pumps, enzyme production to degrade the ABX, gene 
mutations, and modification of active sites to inhibit ABX binding. Pathogens have figured out how to 
dodge modern ABX and proliferate with minimum effort or effect on their normal cellular processes, with 
some pathogens being resistant to all known ABX available in the US.16 It is urgent that more research is 
done to identify new classes of ABX compounds that pathogens do not develop resistance to quickly.  
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1.2 AMPs as a solution to ABX resistance 
AMPs are potential lead candidates as novel antimicrobial agents due to their broad spectrum 
activity as they have been reported to be inhibitory towards bacteria17–21 , fungi22,23, viruses24, parasites25–
28, and cancer29,30. The development of AMPs as therapeutics has been investigated for decades.31 AMPs 
could represent a unique drug class to fight drug-resistant pathogens, as they can be used alone as a last 
line of defense or in synergy with existing ABX to lower the dosages needed to kill pathogens.32,33 One 
reason that AMPs are sought-after as therapeutics is that this class targets the cell membrane of 
pathogens, which is something that is unlikely to stimulate resistance.8 The mechanism is non-specific, 
and the amount of energy needed for a cell to change their entire cell wall composition would likely kill 
the cell.8 AMPs are short (11-100 AAs), usually cationic with a few anionic exceptions34, amphipathic 
peptides that are found ubiquitously in nature and are important to the innate immunity of a multitude of 
animals, insects, and plants.35 AMPs are mainly α-helical17,20,36 but can adopt β-sheet18,37, loop38,39, 
cyclic37,40, and disordered structures.41 Most AMPs selectively target bacteria based on cell wall 
composition.42 The composition of the lipid bilayer in bacteria is comprised of mostly negatively charged 
lipids, mainly phosphatidylethanolamine (PE) and phosphatidylglycerol (PG) with some cardiolipin and 
phosphatidylserine (PS).43 Mammalian cells are zwitterionic and, unlike bacteria, are made up of mostly 
neutral lipids with negatively charged lipids residing on the opposite face of the bilayer.44 Mammalian 
cell membranes are composed of ~25% cholesterol and ~10% sphingomyelin that induce an overall more 
rigid bilayer that increases order and inhibits interaction of AMPs that could lead to specificity for 
bacterial cells.42,44,45 G(-) bacteria have an outer and inner membrane with the outer membrane being 
covered in LPS.43 In G(-) bacteria, the initial attraction of the AMP to the bacterial cell is electrostatic 
between the cationic peptide and the LPS where the AMPs displace Ca2+ and Mg2+ on the LPS and 
subsequently bind, causing outer membrane disruption and uptake of the AMPs.12 The cytoplasmic 
membrane is then targeted where translocation or membrane disruption occurs.12  Conversely, G(+) 
bacteria do not have an outer membrane but do have negatively charged components on their cell wall 
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called lipoteichoic acid and wall teichoic acid.43 These negatively charged components make up 60% of 
the cell wall mass, while the rest of their cell wall is composed of a thick wall of peptidoglycan.43  
Expanding upon the various advantages of AMPs as therapeutic options, including selectivity for 
bacterial cells, there are metal binding motifs that utilize metal ions abundant in the body such as Cu2+ 
and Zn2+ to potentiate greater activity. For example, the amino-terminal Cu2+ and Ni2+ (ATCUN) binding 
motif and the HXXXH motif bind Cu2+ and Zn2+, 
respectively.36,46 Both of these motifs include histidine, 
which is important for metal binding and is intriguing 
because of its pH dependent activity. The pKa of 
histidine is 6; therefore, at pH lower than 6 the histidine 
will carry a +1 charge that confers higher activity likely 
due to the increased charge of the peptide. The ATCUN 
motif is naturally found in albumin, histatin, and 
protamine P2a.46  The ATCUN motif is located at the N-
terminus of a peptide and is composed of H2N-XXH, 
where the XX component of the motif can be any amino 
acid except for proline.46 Cu2+ is bound in a square planar 
geometry to the free N-terminus, the backbone of the two 
deprotonated Namide, and the imidazole ring of histidine 
(Figure 2).46 The ATCUN motif has been postulated to 
induce higher activity due to the production of ROS that 
are produced through redox cycling of Cu2+ to Cu3+ at the 
membrane interface (Figure 2).47  ROS can oxidize lipids 
or if the peptide is intracellular, can oxidatively nick and 
cleave DNA and in some cases become linearized 
 
 
Figure 2. (A) ATCUN sequence without and B) with  
Cu2+ bound (C) Fenton-type Cu2+ to Cu3+ redox cycling 
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leading to cell death.47 Multiple examples exist where the ATCUN motif produces ROS that target the 
membrane and oxidizes lipids in the bilayer.48,49 The addition of the ATCUN motif to several AMPs has 
been investigated and an increase in activity was reported showing that this metal binding motif can 
potentiate activity by utilizing two mechanisms: (1) pore formation and (2) lipid peroxidation.50,51 One 
example showed that when WRWYCR, an intracellular peptide known to enter cells and bind to Holliday 
Junctions, is conjugated to an ATCUN motif, the peptide is able to produce ROS and cleave DNA and 
RNA but only when the ATCUN motif is present.52 The HXXXH motif has recently been examined for 
Zn2+ binding.36 Previously, the AMP clavanin A, isolated from Steyla clava, has shown a 16-fold increase 
in activity against E. coli when Zn2+ is present.36 It was elucidated through the use of alanine mutants that 
the HXXXH motif is responsible for the Zn2+ binding and potentiating activity.36  
1.3 Mode of action of AMPs 
There are several mechanisms for AMPs to target and kill pathogens. Membrane lytic activity has 
been noted for almost all AMPs that have been presently isolated with exceptions that will be discussed 
later. Disruption of the membrane is the major mechanism of this class of molecules with clear and well-
studied examples including magainin 2 and melittin.17,53 The amphipathic nature of α-helices and β-sheets 
allow membrane interactions with the polar lipid heads and fatty acid tails that causes membrane 
disruption seen in AMPs but is not required for membrane activity.42 In order to have membrane 
disrupting activity against pathogens, the density of AMPs needs to reach a certain threshold to cause 
lysis of cells, commonly in the µM range.29 When the peptide:lipid ratio needed for disruption is >1:100 
but < 1:1000, the peptide can be characterized as an AMP, while if the ratio is >1:1000, it is considered a 
peptide toxin as is the case with melittin and alamethicin.42 AMPs prefer to target at curvatures or at the 
septa of multiplying cells and do so faster than with nonseptated cells, causing cell shrinkage in both G(-) 
and G(+) bacteria.54,55 The AMPs generally attack at a curvature where new cell membrane is being 
synthesized, specifically at the septa in a dividing cell or at a pole of a single cell.54 This may be due to 
several reasons such as the lower lipid to peptide ratio at the newly synthesizing bilayer or the shape of 
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the lipid at the curve.54. Once the peptide makes a hole, the pore causes rapid depolarization of the cell 
membrane and leakage of cellular contents that causes cell death.56 The peptides accumulate on the 
surface of the membrane and then organize themselves to form pores.35 Multiple mechanisms describing 
how membrane disruption occurs have been proposed, including the carpet model, toroidal pore model, 
and the barrel stave model (Figure 3). The carpet model suggests that the AMPs lay parallel to the bilayer 
to create a “carpet” where pores are formed, and the bilayer collapses onto itself and destroys the 
membrane.57 The toroidal pore model proposes that the curvature of the membrane is affected when the 
peptide integrates perpendicular to the membrane and induces curvature while disrupting the membrane 
separation of the lipid tails and polar head groups of the lipids.42 The barrel stave model describes how 
peptides interact with each other to form ion channels in the bilayer by aligning perpendicular to the 
membrane and forming water-filled pores that traverse the membrane.42,57 The toroidal pore and barrel 
stave models are similar and both implicate that cell death occurs when the cellular contents leak out of 
the cell.57  
One of the most studied AMPs to date is magainin 2 (GIGKFLHSAKKFGKAFVGEIMNS), a 
membrane active peptide.17 It was originally isolated in 1987 from the epidermis of the frog Xenopus 
laevis.17 It is an α-helical peptide that is potent towards G(+) and G(-) bacteria, as well as fungi.17 
Magainin 2 selectively targets bacteria, as it does not lyse human erythrocytes.58 When sterols were 
present in model membranes, the lytic ability was drastically reduced, again indicating selectivity for 
bacterial lipid composition and cell wall components.58 The major mode of action is disruption by the 
formation of pores in the bacterial cell membrane and lysis of the inner membrane of G(-) bacteria if the 
lipids were acidic.59,60 It has been postulated that pores are formed from the α-helical peptide that spans 
the bilayer to aggregate and make water-filled pores.59,60 These pores alter the permeability to ions and 
depolarize the membrane.59,60 In one proposed mechanism, magainin 2 becomes α-helical in the presence 
of the lipids and forms a pore, lipid flip-flopping occurs, and peptides enter the periplasmic space to target 
the inner membrane, alter both lipid asymmetry and cause depolarization of the membrane.59,60 Similarly,  
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melittin (GIGAVLKVLTTGLPALISWIKRKRQQ), a 26-AA peptide that makes up 50% of the dry 
weight of honey bee venom, is highly membrane lytic against bacterial and mammalian cells.53,56 This 
peptide, derived from the European honeybee (Apis melifera) forms an amphipathic helix, has a net 
 
 
 
 
Figure 3. Models of how membrane disruption can occur, where the blue rods represent the peptides and 
the lipid heads are orange (A) carpet model (B) toroidal pore model (C) barrel-stave model 
 
A 
 
B 
 
C 
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charge of +6, and a hydrophobic C-terminus comprised of KRKR.56 A proline in the middle of the 
sequence causes a break in the peptide structure, but it is still α-helical overall.56 Melittin and the related 
alamethicin are classified as peptide toxins due to their strong lytic abilities, with membrane 
depolarization being their major mode of action.42,56 A concentration of 1 μg/mL is sufficient for melittin 
to lyse erythrocytes exhibiting its potent lytic ability.56 Although melittin has been labeled a toxin, it has 
been utilized for its anti-inflammatory61 and anti-cancer53 properties indicating that whether peptides are 
very hemolytic or toxic to human cells they can still be used for human applications. Ixosin 
(GLHKVMREVLGYERNSYKKFFLR), another membrane targeting AMP, has a different mechanism 
of action. Ixosin is a peptide from the salivary glands of Ixodes sinensis, a hard tick.20 The mechanism of 
action against G(-), G(+) bacteria, and fungi, is pore formation and the oxidization of lipids, through an 
ATCUN motif.20,48  In addition, ixosin exhibited synergistic activity with ixosin B, another antimicrobial 
peptide from ticks, due to the localization of the two peptides.48 Ixosin has minimal cell toxicity when 
tested with HeLa and HEK293 cells indicating that this could be a potential therapeutic that can utilize 
metals already in the human body and have synergistic activity to potentiate activity.48  
Intracellular targeting has also been observed with numerous peptides including buforin II62, 
indolicidin45,63, tachyplesin I64,65, apidaecin66, and PR-3967. These AMPs have three major targets, which 
are DNA, RNA, and protein synthesis. Once inside the cell, there can be specific binding or electrostatic 
interactions between positively charged AMPs and negatively charged DNA and ribosomes. Peptides 
with a high content of specific residues, such as proline and arginine, tend to enter cells easily and have 
intracellular mechanisms.67 Two modes of translocation have been demonstrated with some AMPs that 
spontaneously translocate or those that can utilize proteins to transport into the cell. One peptide that can 
spontaneously translocate is buforin II (TRSSRAGLQFPVGRVHRLLRK), which was isolated from the 
N-terminus of the histone H2A from the stomach of Bufo gargarizans and was found to be highly active 
against fungi as well as G(+) and G(-) bacteria.68 This 21-AA peptide exhibited no cell lysis even at 5X 
MIC, indicating a purely intracellular mechanism with high affinity DNA and RNA binding.68 Even at 
Portelinha 13 
 
 
sub-MIC concentrations the peptide was able to translocate the cell membrane without causing membrane 
defects or using proteins to translocate.68 The C-terminus of buforin II contains the DNA binding moiety 
and is α-helical in solution with a proline hinge in the middle of the peptide giving a unique helix-hinge-
helix structure that contributes to its wholly intracellular mechanism because proline residues cause a 
rigidity due to the ring structure that is not seen with any other AAs.19 Another peptide capable of 
translocating is indolicidin (ILPWKWPWWPWRR), a 13-AA peptide isolated from bovine neutrophils, 
that is tryptophan- and proline-rich and exhibits an extended structure in the presence and absence of 
lipids.41,45 Indolicidin was able to permeate the outer and inner membrane of E. coli within minutes of 
interaction with the membrane but no cell lysis has been observed, even when tested at 3X MIC.45,63 
Further analysis of the mechanism revealed that indolicidin causes filamentation or elongation of E. coli, 
which is indicative of inhibition of DNA synthesis.63 Not only does indolicidin inhibit DNA synthesis, it 
also inhibits DNA processing enzymes, binds directly to abasic DNA sites, ssDNA, and dsDNA, and 
causes DNA crosslinking.69,70 These errors can result in loss of DNA replication abilities.69,70 At high 
concentrations, indolicidin appeared to halt protein synthesis within five minutes of incubation, though 
this seemed to be secondary to inhibition of DNA synthesis.63  
 The target of an AMP can also change with increasing concentration, which is not uncommon for 
AMPs. One such case is with tachyplesin I (KWCFRVCYRGICYRRCR), a 17-AA AMP, which was 
isolated from hemocytes of the horse shoe crab Tachypfeus tridentatus.18 The peptide structure was 
elucidated by NMR spectroscopy and has a unique antiparallel β-sheet structure with two disulfide bonds 
and distinct hydrophobic/hydrophilic sides indicating an amphipathic structure.71 Tachyplesin I is active 
against G(-) and G(+) bacteria, but the mode of action of tachyplesin I has been debated in the past. It has 
been observed to act on intracellular targets, 65,71,72 have a high affinity for binding LPS,18 and other 
membrane disruption properties.72,73 It was demonstrated to bind at the minor groove of DNA when the 
disulfide bonds are intact indicating the importance of the rigid β-sheet structure in the DNA binding 
abilities.65,71 Recently, it was determined that tachyplesin I has a concentration dependent mechanism 
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because while membrane disruption seems to be the primary target, sublethal doses can influence the 
esterase activity of bacteria and cause cell death.72,73 Tachyplesin I in a β-sheet has also been seen to form 
anion selective pores that allow the internalization of approximately 200 peptides.74 It is suspect whether 
DNA interactions occur intracellularly because of the reducing environment inside of the cell and the 
necessity for the cysteine bonds to allow for DNA binding.  
Other AMPs use transporter channels to enter the cells rather than being able to translocate to the 
inner membrane. Apidaecin (GNNRPVYIPQPRPPHPRL), a proline- and arginine-rich peptide, has a 
stereospecific mechanism of action.75 This peptide can translocate without causing cell lysis and it has 
been postulated that it uses transporters to enter the cell.66 While most AMPs activity is unaffected by a 
change from L to D AAs, apidaecin has a complete loss of activity when made with D form AAs, 
indicating that the target has some specificity for binding.75 It was found that protein synthesis was the 
target of apidaecin and that it was most likely binding to ribosomes to inhibit protein synthesis.66 
Apidaecin also binds bacterial Dna K, a heat shock protein, with sequence specificity, while it  
nonspecifically binds the chaperone GroEL.76 Interestingly enough, the peptide did not interact with 
HSP70, the Dna K analouge in human cells, and seemed to specifically target and inactivate bacterial Dna 
K indicating the potential for this peptide as a therapeutic agent.76 Apidaecin interacts with LPS by 
binding to chaperone proteins, the peptide may potentially transport to the inside of the cell where it could 
bind to DNA and ribosomes to inhibit growth.66,76 Another peptide rich in proline and arginine residues, 
PR-39 (RPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP), also has intracellular activity mediated by 
active transportation to enter the cell.67 PR-39 is a 39-residue peptide that is comprised of almost 50% 
proline residues.67 It enters the cell after eight minutes and kills 75% of cells within three minutes of 
incubation by inhibiting DNA synthesis and causing protein degradation.67 SbmA is an inner membrane 
protein in E. coli that is likely part of an ABC transporter that proline rich AMPs, such as PR-39, can use 
for transport into cells.77 PR-39 and other proline-rich AMPs use this inner membrane protein to enter the 
cell and bind their intracellular targets.77 
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AMPs can utilize different modes of action whether it be multiple membrane or intracellular 
targets that lend them to become alternatives to modern ABXs. In addition to this, they have also 
appeared in several cases to be selective for pathogenic membranes indicating selectivity that is crucial to 
therapeutic development. AMPs have shown that they can be used in combination with each other, as in 
the case of ixosin, or can be used synergistically with ABXs.32,33 Moreover, AMPs can utilize metal ions 
that are already abundant in the human body to potentiate greater activity on pathogens.36,48 The variations 
in AA composition and secondary structure shows that hundred and thousands of combinations can be 
synthesized, including the addition of DNA or protein binding moieties that can kill cells based on 
different and specific mechanisms that will be difficult for the bacteria to confer resistance to. AMPs have 
great potential to be a novel class of drug molecules.  
1.4 Piscidins and gaduscidin-1 as therapeutic AMPs 
Recently, a new group of piscidins were isolated named the gaduscidins that have multiple metal 
binding motifs and represent a unique facet of the piscidin family, as most piscidins have no metal 
binding motif or they only have an ATCUN motif. The piscidins are a class of α-helical, histidine-rich 
AMPs from teleost fish that were originally isolated from mast cells of hybrid striped bass (Morone 
saxatilis x M. chrysops).78 The isolation of the piscidins was the first report to find AMPs in 
immunologically relevant cells.78 Three piscidins were recovered and named piscidin-1, -2, and -3 (p1, 
p2, p3).78 The piscidins were originally found in mast cells but were later isolated in granules as well. 
Interestingly, the piscidins were later isolated in granules but were not found in phagosomes.21 The 
peptides were transported to the phagosomes instead, suggesting extracellular and intracellular killing 
abilities of piscidin.21 The peptides were found to be moderately hemolytic, with broad spectrum activity 
against fish pathogens and parasites25,27,28, human related pathogens78, fungi22,79, and viruses24 that retained 
activity even in high salt conditions.25 The sequences of these piscidins (Table 1) show a highly conserved 
N-terminus with H, F, and I residues, where p2 is identical to p1 with the exception of an R to K 
mutation.78 All three piscidins have an ATCUN and an HH or a bis-H motif. Natural piscidins exist as a  
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mixture of amidated and nonamidated forms of peptide.25 The effect of nonamidated versus amidated p1 
and p3 were examined via multiple techniques including NMR spectroscopy, and it appears that 
amidation did not change the α-helicity of the peptide or the perpendicular orientation of the peptide to 
the PC/PG lipid bilayer.25 The structure of p1 was determined by NMR in the presence of trifluoroethanol 
(TFE) and showed an α-helical conformation from residues 8 to 17 with disordered N- and C-termini.80 
This study also used a mixture of lipids, with 20% of them being negatively charged to induce a pseudo-
G(-) membrane, and found that p1 did not induce any voltage-dependent channels indicating that the 
barrel stave model is not consistent with the data while the toroidal pore model better explains the 
mechanism of p1 and p2.80 Extracellular and intracellular mechanisms, such as nuclease activity, have 
been observed for p1 and p3.81 When compared against E. coli persister cells and biofilms, p3 was more 
Table 1. Summary of selected peptides in the piscidin family with all H residues in bold 
 
Peptide Sequence Organism Accession 
Number 
Piscidin-1 FFHHIFRGIVHVGKTIHRLVTG 
Morone saxatilis x M. 
chrysops  Q8UUG0 
Piscidin-2 FFHHIFRGIVHVGKTIHKLVTG 
M. saxatilis x M. 
chrysops  Q8UUG2 
Piscidin-3 FIHHIFRGIVHAGRSIGRFLTG 
M. saxatilis x M. 
chrysops  P0C006 
Piscidin-4 
FFRHLFRGAKAIFRGARQGXRAHKVV 
SRYRNRDVPETDNNQEEP 
M. saxatilis x M. 
chrysops  L0CKG3-1 
Gaduscidin-1 
(pis-1) FIHHIIGWISHGVRAIHRAIH Gadus morhua  D4HRB8 
Gaduscidin-2 
(pis-2) FLHHIVGLIHHGLSLFGDRAD G. morhua  E2EZU3 
 Pis-2β FLHHIVGLIHHGKLDMYRSNN G. morhua  E7D8W6 
Pleurocidin GWGSFFKKAAHVGKHVGKAALTHYL 
Pleuronectes 
americanus  P81941 
Epinecidin-122–42 FIFHIIKGLFHAGKMIHGLV Epinephelus coioides  Q6JWQ9 
Myxinidin GIHDILKYGKPS Myxine glutinosa L.  --- 
Dicentracin FFHHIFRGIVHVGKSIHKLVTG Dicentrarchus labrax  P59906 
Chrysophsin-1 FFGWLIKGAIHAGKAIHGLIHRRRH Chrysophrys major  C3KHI8 
Chrysophsin-2 FFGWLIRGAIHAGKAIHGLIHRRRH C. major  P83546 
Chrysophsin-3 FIGLLISAGKAIHDLIRRRH C. major  P83547 
TP1 FDWDSVLKGVEGFVRGYF Oreochromis niloticus  I3KPK0 
TP2 GECIWDAIFHGAKHFLHRLVNP O. niloticus  L0CKQ8 
TP3 FIHHIIGGLFSVGKHIHSLIHGH O. niloticus  L0CMD2 
TP4 FIHHIIGGLFSAGKAIHRLIRRRRR O. niloticus  L0CKG3 
TP5 QLQGKQVSGEVVQKVLQELIQSVAKP O. niloticus  L0CM08 
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active than p1 due to the nuclease activity of p3, while p1 is more membranolytic.81 Comparing p1 and 
p3, p1 was seen to be more antimicrobial and more hemolytic than p3 when tested against G(+) bacteria.82 
Potent antifungal activity was observed for p1 and p3 and they were more active than amphotericin B, an 
antifungal ABX, when tested against Trichosporon beigelii and Candida albicans79. It was found that p1 
acted against the fungi by disrupting the membrane via pore formation.79 Comparatively, p2 was found to 
be active against water mold, multiple parasites, and to have partial synergism with Cu2+.25,26 It was also 
observed to be active against multiple types of fungi including C. albicans via a pore formation 
mechanism22 and has been reported to have synergy with a hepcidin peptide that was also isolated from 
hybrid striped bass gills83.  
 
Figure 4. (A) Piscidin alignment of mature peptide sequences, showing conserved residues. Accession 
numbers are as follows: p1 Q8UUG0, p2 Q8UUG2, dicentracin  p3 P0C006, Gad-1 D4HRB8, 
Chrysophsin-1 P83545, Chrysophsin-2 P83546, Chrysophsin-3 P83547, Epinecidin-1 Q6JWQ9, Gad-2 
E2EZU3, Pis-2β E7D8W6,  Pleurocidin P81941, TP4 L0CKG3, TP3 L0CMD2 
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Later, piscidin 4 (p4) was isolated from mast cells of M. saxatilis x M. chrysops.84 This piscidin is 
44-AAs long, twice the length of the other piscidins, and unlike the others, it only weakly formed an α-
helix.84 The sequence varied as well with the peptide having a hydroxylated W in position 2084 and only 
two H residues. Similar to p1, p4 showed leakage from vesicles indicating that its likely target is the 
membrane and that potentially the toroidal pore model may be the mode of action of p4.85  The hemolytic 
ability of p4 is lower than its active concentration against human and fish pathogens.84,85  
Since the elucidation of the first piscidins, multiple others have been identified from teleost fish, 
more specifically from the Perciformes order.78,27 The piscidin family is comprised of other AMPs 
including pleurocidins, moronecdins, gaduscidins, myxinidin, epinecidin, chrysophsins, and dicentracin 
(Figure 4). The aforementioned piscidin peptides have shown potent broad spectrum activity and have 
high H content with several of them having ATCUN motifs that potentiate their activity.86 The different 
piscidins are 12 to 44 AAs and can have low sequence homology to each other but are all α-helical to 
some extent. The piscidin family are characterized by a four exon/three intron gene sequence, with few 
exceptions, and a highly conserved N-terminus with H, F, and I residues, as well as a highly conserved 
propeptide region (Figure 5).28 Recently, nile tilapia (Oreochromis niloticus), a teleost fish, has been 
found to produce a total of five piscidins named TP1-TP5.29 These peptides range from 18 to 26 residues 
with TP3 and TP4 having high sequence homology to the original piscidins with multiple H residues and 
a conserved N-terminus with I and F residues.29 TP4 is the most active peptide out of the group, with TP3 
and TP4 exhibiting activity against G(-) and G(+) bacteria while TP2 and TP5 showed no activity.29 All 
five were predicted to be α-helical and TP2, 3, and 4 were mildly hemolytic against tilapia erythrocytes 
with TP3 and TP4 being the most hemolytic and TP1 and TP5 not exhibiting hemolytic activity.29 TP3 
may have anti-cancer properties and was deemed not harmful to normal mammalian cells, therefore 
indicating the potential of TP3 to be an anti-cancer agent.29 TP2, 3, and 4 were all isolated in 
immunologically relevant tissues in the fish, again showing similarity to the original piscidins.29 TP3 was 
the only peptide found in the gills while TP2 and TP3 were both found in the head  
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kidney, as well as the epidermis, with TP2 also being found in the spleen.29 TP4 was the only AMP found 
in the intestine, while TP1 and TP5 were not able to be immunostained, therefore it is not clear what their 
role is.29 Under bacterial challenge, TP4 expression was increased 10 to 60 fold in the head kidney, gills, 
and spleen.29 TP2 and TP3 were not seen to be upregulated, indicating the importance of TP4 to the 
overall immune response of the tilapia.29  
TP4 was further investigated by multiple groups, which yielded an NMR structure elucidating the 
importance of the F, I, and L residues in the center of the peptide for the formation of an α-helix.87 The 
peptide has a hydrophobic core at the N-terminus with a cationic C-terminus being important for 
interactions with bacterial membranes and a central α-helix.87 This is interesting because the piscidins 
have conserved these residues throughout, giving more evidence for their need towards the 
amphipathicity and subsequent activity of the peptide. The authors also showed that when the bis-H motif 
at the third and fourth position were substituted for A residues there was a loss in fungal activity, but the 
peptide still retained hemolytic activity when tested with mouse erythrocytes, potentially pointing to the 
need of the conserved bis-H motif for fungal applications.87 The antimicrobial ability of the peptide with 
the A substituted third and fourth position, shows that the activity against MRSA and P. aeruginosa was 
abolished while the S. aureus MIC increased 4-fold when compared to the wild type (WT) peptide.87  
The original piscidins were also independently isolated peptides from the epidermis and gills of 
M. saxatilis x M. chrysops by Lauth et al. and were named moronecidins.88 These two peptides are 
identical to the sequences of p1 and p2 with an additional T residue at the C-terminus of the peptide 
making them 23-AA peptides.88 The two C-terminally isoforms were also seen to be α-helical and have 
activity against fungi and G(-) and G(+) bacteria including MRSA, with activity in the presence of high 
salt content.88 Another peptide with high sequence homology to p1 and p2 is dicentracin, which was 
isolated from head kidney leukocytes of the sea bass Dicentrarchus labrax.89 Interestingly, dicentracin 
showed ~90% sequence homology with p1 and p2 with the only difference from p1 being a S in place of 
the T in the 15th position and a 40-68% homology of the propeptide regions.89 Dicentracin has an ATCUN 
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motif, however, the activity with and without Cu2+ has not been studied. Experiments show that after 24 
hours of acute stress there were increased levels of peptide in the gills, and to some extent the epidermis, 
confirming that the peptide has a role in stress and immunological response though the activity of this 
peptide has not been extensively studied.90  
Another piscidin with an ATCUN motif is myxinidin, which was isolated from Myxine glutinosa 
L. or hagfish.91 Although there are conflicting reports on the activity of this peptide92, it has been reported 
to be active against G(-) and G(+) bacteria, fungi, and fish pathogens.91 This peptide is substantially 
shorter than other piscidins (12-AA residues) but is similar to other piscidins in that the activity is not 
abolished in the presence of up to 300 mM NaCl.91,93 Myxinidin has therapeutic potential, because it was 
not hemolytic when tested with rabbit91 and human erythrocytes.93 There was also low toxicity when 
tested on mammalian cells.94 The peptide was found to be partially α-helical, from residues 2-9, by NMR 
spectroscopy and circular dichroism (CD).93,94 A second study used an alanine walk (an A is substituted 
for each AA for a total of 12 mutants) to probe the essential residues.94 All mutants were ~60% helical in 
TFE indicating that there was no dramatic change in the secondary structure based on the single AA 
substitutions.94  The results showed that the G1, P11, and S12 residues ranked the highest in importance 
for the activity of the peptide.94  
Pleurocidin is one of the largest groups of the piscidin family with the first pleurocidin being 
isolated from winter flounder, Pleuronectes americanus.95 It was found to be prevalent in the mucous 
membranes of the fish95 and was found to be produced in goblet cells of the small intestine.32 
Immunostaining revealed that the peptide is located in the eosinophilic granular cells that are transported 
to inflammation or injury sites as a non-specific defense in the gills.96  The pleurocidin gene has four 
exons and three introns32, like the piscidins, and was observed to kill bacteria in up to 625 mM NaCl.95 
Consistent with other piscidins, the peptide was α-helical in the presence of membranes57, with broad 
spectrum activity95, including activity against clinical fungal isolates.32 It is suggested that activity against 
C. albicans is mediated by the formation of ROS and the eventual membrane depolarization of 
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mitochondria, which then leads to the expulsion of pro-apoptotic factors and eventually apoptosis of the 
cell with either direct or indirect DNA damage.23 Pleurocidin had stronger interactions to anionic lipids 
rather than neutral lipids, indicating some selectivity for bacteria.57,97 Dye leakage was exhibited in the 
presence of a neutral and negatively charged lipid mixture (PC/PG) that would mimic G(-) bacteria.97 
NMR studies revealed in plane alignment with the lipids similar to magainin 2.97 The fully protonated 
histidine-rich peptide, where the charge increased from +5 to +8, was also studied by NMR, however, the 
results showed no change in membrane disruptive activities indicating that the presence of H is likely not 
related to increased membrane disruption at a lower pH.97   
Additionally, there are multiple isoforms of chrysophsin, a piscidin, that were isolated from 
granule cells in the gills and epithelial cells of Chrysophrys major or red sea bream.98 All of the peptides, 
named chrysophsin -1, -2, and -3, are C-terminally amidated and range from 20 to 25 AAs in length.98 
They all exhibit an α-helical conformation in the presence of a membrane mimetic solvent and a 
disordered structure in water.98 These peptides are similar to p1-p3 in that they are hemolytic to human 
erythrocytes.98 They are active against G(-) and G(+) bacteria and chrysophsin-3 was tolerant to up to 160 
mM NaCl where the other two could withstand 320 mM salt and remained bacteriocidal.98 A unique and 
conserved feature is the RRRH sequence at the C-terminus of the peptide.98 Chrysophsin-1 showed a 
mechanism of pore formation, which was enhanced with negatively charged lipids.99 When tested against 
human lung fibroblast cells, chyrsophsin-1 was highly toxic, but less so without the RRRH motif, which 
was found to be important for α-helix formation and pore formation.99 Chrysophsin-1 has also shown 
activity against numerous oral pathogens such Enterococcus faecalis, Actinomyces viscous, and 
Streptococcus mutans biofilms, which were thinned after exposure and 90% of cells were killed within 
four hours of incubation.100 Anti-cancer properties by lysing membranes has also been reported.30 
Chrysophsin-1 has been observed to have anti-inflammatory properties by inhibiting TNF-α secretions 
that normally lead to inflammation, which has not been observed with piscidin.30 
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Potentially one of the most studied and longest piscidins is epinecidin-1, which is 67-AAs and is 
commonly truncated to a 21-AA segment.101 It was found to localize in the head kidney, epidermis, and 
intestines of the orange-spotted grouper fish Epinephelus coioides.102 Similar to other piscidins, the gene 
sequence consists of three introns and four exons and had activity against G(-) and G(+) bacteria, fungi, 
and yeast.101 The peptide is not hemolytic towards tilapia erythrocytes but are hemolytic to human 
erythrocytes.103 Epinecidin-1 can be a powerful therapeutic in humans and fish, this being exemplified by 
increased immunity to Vibrio vulnificus in fish after one injection of epinecidin-1.102 In addition to 
affording protection to fish, a study investigated protection against P. aeruginosa infection in mice, which 
can cause septic shock.103 The authors found that a dose of 0.005 mg/g protected the mice from sepsis, 
and the peptide showed no toxicity to the mice even at high concentrations such as 50 mg/kg where other 
AMPs have been seen to be toxic in mice.103 Moreover, there was a 100% clearance of MDR P. 
aeruginosa within 48 hours of peptide administration and the peptide affected expression of other genes 
such as interleukins and interferons, which modulate the immune system.103 Additionally, it was 
postulated that the peptide binds LPS and blocks cytokines, such as TNF-α, and reduces endotoxin release 
and inflammation in the mice similar to the chrysophsin family of peptides.103 Epinecidin-1 was also 
found to have anti-cancer properties by disrupting the membrane and having lytic activity against HT1080 
and HeLa cells at 2 µg/mL.104 Epinecidin utilizes pore formation and can potentially trigger apoptosis via 
a pathway different from caspase, which is traditionally targeted by anti-cancer drugs and rather 
specifically targets necrosis gene expression.104 Epinecidin-1 is also active against MRSA.105 Mice studies 
have reported that the peptide not only reduced the bacterial count of MRSA more effectively than 
vancomycin in an open wound but also helped to induce wound healing and reduced the expression of 
inflammatory cytokines.105 An additional study was repeated using a pig model in vitro and showed 
similar results indicating that epinecidin-1 could be a potential clinical option for treatment of MRSA.106  
Additionally, activity was seen against Propionibacterium acnes, C. albicans, and Trichomonas vaginalis 
indicating larger therapeutic applications including use in creams and topical medications.107 
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Overall, the piscidin family has yielded multiple AMPs that can be used as therapeutic agents in 
both fish and human. The therapeutic value of these compounds is enhanced by the presence of metal 
binding motifs, especially in the presence of both the ATCUN and HXXXH motifs. Gaduscidin 1 (gad-1) 
specifically has both of these motifs and has not been extensively studied. Gad-1 is a piscidin AMP that 
originated from Atlantic cod (Gadus morhua).86 It was reported by two groups independently with its 
paralogue and a splice variant, gad-2 and gad-2-β (alternatively named pis1, pis2, and pis2-β). 28,86 Gad-1 
(FIHHIIGWISHGVRAIHRAIH, Figure 6) is found in immunologically relevant tissues of G. morhua 
such as the mucus membranes, gills, spleen, and head kidney.108 In addition to immunological tissues, 
gad-1 was isolated in the swim bladder and kidneys, which are implicated in osmosis and buoyancy rather 
than immune response.108 Gad-1 is found in oocytes and in low levels in the brain, indicating a potential 
role in cell development or tissue repair.86,108 This tissue dispersity could imply that gad-1 does more than 
just protect the fish against pathogens. G. morhua has a unique immune system in that they produce no 
MHC class II, CD4, and invariant chain, all important to the adaptive immune system.109 Therefore, 
AMPs including the gads, hepcidin110, β-defensins111, and codCATH112 are crucial to the immune system 
of these fish. The presence of gad-1 in organs that interface water including the mucus membranes and 
gills, show great importance in protecting the fish before and after an infection occurs.  
Gad-1 has a 50% sequence homology to p1 and a 45% sequence homology to both p2 and p3. 
Interestingly, a sequence alignment with several piscidins shows that H3, H4, H11, and H17 are all 
conserved residues (Figure 4). The sequence of gad-1 is also similar to TP4 due to the bis-H motif in the 
third and fourth positions and the H17 and R18 arrangement at the C-terminus of the peptide. Gad-1 is 
one of the only piscidins, with the exception of pleurocidin and chrysophsin 1 and 2, to have a W residue. 
The sequence is also similar to p3 in respect to the R residues in position 14 and 18 and the N-terminus of 
FIHH is only seen with gad-1, TP3, TP4, and p3. Again, similar to other piscidins, there is a three 
intron/four exon gene sequence.28  
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Figure 6. (A) Helical wheel diagram of gad-1 and (B-D) I-TASSER predictions on the structure of gad-, 
where blue denotes the C-terminus and red denotes the N-terminus 
A B 
C D 
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The mechanism has not been elucidated for gad-1, however it has been suggested that it is 
membrane disruption.113 Gad-1 has been seen to have broad spectrum antimicrobial activity28,113 but did 
not have antiparasitic activity, while its paralog gad-2 was active against Tetrahymena pyriformis 
implicating their different roles in the immune response.28 Intriguingly, the activity of gad-1 does not 
increase with a decrease in pH unlike many other histidine containing AMPs.113 It has been suggested that 
because the charge of the peptide does not change substantially (+3 to +8) that this is the reason there is 
no change in activity at pH 5, which is similar to pleurocidin.113 Gad-1 contains a total of five H residues 
including an HXXXH and an ATCUN motif, both associated with metal binding and potentiating activity 
against pathogens. Gad-1 is one of the only known piscidins with both of these motifs. Our interest on 
this peptide was due to the metal binding motifs and how gad-1 is utilized in the natural defense of G. 
morhua. Gad-1 exhibits an almost perfect amphipathic helix, which unfortunately has been correlated to 
higher hemolysis activity against erythrocytes.113 The metal binding activity of gad-1 has never, to our 
knowledge, been studied, while the role of histidine in the peptides have been studied using molecular 
dynamics (MD).114  
Previous MD studies of gad-1 reveal that H3 and H4 are important to lipid interactions.114 When a 
pore is formed H17 and R18 interact with the planar part of the bilayer.114 No implications for H11 or 
H21 were revealed with MD studies. The N-terminus, where there is less helical content, also had a 
greater tendency to interact with the pore than the C-terminus when the H residues are not protonated.114 
If protonated, H3 interacts solely with the rim of the lipids in the pore, which reinforces the importance of 
the N-terminal H residues.114 The bis-H motif may have affinity for close proximity to lipid bilayers, 
whether they are charged or not.114 An NMR study was conducted and showed H21 is not in the helical 
region of the peptide and that there is a helix break from residue 9 to residue 12 which corresponds to S10 
and H11.113 The MD and NMR studies did not consider the Cu2+ bound state of the peptide or investigate 
any metal binding activity with Cu2+ or Zn2+.  
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CHAPTER 2 
Investigating gad-1 for metal ion binding and antimicrobial applications 
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2.1 Introduction 
Herein, gad-1 metal binding abilities were examined along with the role of H in potentiating 
antimicrobial efficacy. A set of modified peptides, where each H was substituted for an A, was 
synthesized (Table 2). The Cu2+ and Zn2+ binding of gad-1 were studied using spectroscopic techniques  
 
 
 
 
and mass spectrometry with the mutant peptides to determine how each H may play a role in metal 
binding. The antimicrobial activity the mutant peptides against G(+) and G(-) bacteria that include fish 
and human pathogens, were determined. H3 proved to be important to the activity of gad-1, as without it 
Cu2+ cannot be bound and the ATCUN motif is rendered inactive. H17 also showed importance to the 
activity of the AMP while H4 and H21 did not have as much of an effect on the activity based on MIC 
measurements with a multitude of pathogens, except for the exception of Vibrio spp. with H4A. Previous 
MD studies showed substantial interaction of the lipid bilayer with the H4, therefore it is interesting that 
the activity of the H4A mutant is not markedly different from the WT peptide.  
The antimicrobial mechanism was explored and was determined to be membrane disruption with 
no suspected intracellular activity. A β-galactosidase leakage assay showed that the induced leakage from 
cells for all mutants were ~50% the amount Triton X-100 showing that pores were formed. Another 
interesting facet of the mechanism is that gad-1 could peroxidize lipids at a significantly higher rate when 
Cu2+ was present. It was shown that the H3A mutant did not significantly increase the rate of lipid 
peroxidation when Cu2+ was added, indicating that the ATCUN motif is responsible for some of the lipid 
peroxidation activity. It was concluded that gad-1 was able to bind Zn2+ with very low affinity to the 
Table 2: Summary gad-1 mutant peptides 
Peptide Sequence 
Gad-1 FIHHIIGWISHGVRAIHRAIH 
H3A FIAHIIGWISHGVRAIHRAIH 
H4A FIHAIIGWISHGVRAIHRAIH 
H11A FIHHIIGWISAGVRAIHRAIH 
H17A FIHHIIGWISHGVRAIARAIH 
H21A FIHHIIGWISHGVRAIHRAIA 
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HXXXH motif, but this site may be another potential Cu2+ binding site. The α-helicity of gad-1 and the 
mutants were characterized using CD. Moreover, the hemolysis to human erythrocytes of the peptide and 
mutants were found to probe the possibility for using gad-1 as a therapeutic for human usage. Other 
potential applications for gad-1 would be to use it in farm fish feed, as it was shown previously that gad-1 
is not hemolytic to cod erythrocytes28, as well as using transgenic plants115 and fish116 to boost their 
immune system. Atlantic cod is a very economical fish especially in Norway, where farms are often 
decimated by fishborne illness caused by a variety of pathogens.108,111 This can have major economic 
impact and an impact on the general public, as if they consume the fish they can also become ill. The 
major pathogens are Vibrio and Aeromonas species that are both found in brackish water and can cause 
necrotic tissue damage and hemorrhaging to the fish.117 If other fish have open wounds they will be easily 
infected by the pathogens and spread to the blood and cause septicemia.117 Gad-1 could be utilized in fish 
farms to reduce the spread of infection to other fish and humans, as well as therapeutic applications for 
human infection and disease.  
2.2 Metal ion binding   
Several peptide mutants of gad-1 (Table 2) were synthesized to determine the role of H in metal 
ion binding of gad-1. Gad-1 has both an ATCUN motif and an HXXXH motif that can bind to Cu2+ and 
Zn2+, respectively. To elucidate whether gad-1 binds to Cu2+ and Zn2+ and the residues involved in 
binding, MS was used. The peptides were incubated with varying ratios of Cu2+ to determine whether 
binding occurs and the stoichiometry of binding. Gad-1 was assumed to bind at least one Cu2+ ion due to 
the presence of the ATCUN motif. After injecting the peptide sample with different ratios of Cu2+, it was 
shown that there was binding to at least two sites in the WT peptide based on the masses (Figure 7, Table 
3). When 2 equivalents of Cu2+ was added, the [G1-3H+] and [G1-4H+] peaks, where G1 is gad-1, had 
similar intensities to the masses corresponding to one Cu2+ being bound to gad-1. There were also smaller 
peaks correlating to gad-1 with two Cu2+ ions bound, which intensified when 5 equivalents of Cu2+ was  
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Figure 7. MS data indicating that two Cu2+ ions bind to gad-1 (A) gad-1 with no added Cu2+ (B) gad-1 with 1X Cu2+ (C) 
gad-1 with 2x Cu2+ (D) gad-1 with 5X Cu2+ 
A B 
C D 
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added. The second binding site is assumed to be the HXXXH motif due to the spacing of the H residues 
in the helix and the affinity of H to binds Cu2+. Several attempts to visualize the Cu2+ bound in a square 
planar manner were made, as a peak at 525 nm has been observed with many ATCUN peptides.46 The 
concentration of gad-1 was varied from 0.3 mM to 1 mM and Cu2+ and was titrated in H2O (data not 
shown) and buffer solutions (Figure 8). No peak was observed, however this is not uncommon and could 
be due to the high peptide concentration that may cause aggregation. The appearance of a peak was seen 
Table 3: Summary of apo-gad-1 and bound-gad-1 masses, where black indicates apo-gad-1, red indicates  
one Cu2+ or Zn2+ bound, and blue indicates two Cu2+ bound 
Sample Mass Expected (Da) Mass Observed (Da) 
Gad-1 1236.0, 824.3, 618.5, 495.0 1236.4, 824.4, 618.8, 495.0 
1X Cu2+ 1267.3, 844.8, 633.6, 506.9 1235.9, 844.9, 824.4, 634.1, 618.5, 507.3, 494.9  
2X Cu2+ 1299.0, 866.0, 649.5, 519.6 1236.4, 866.0, 844.6, 824.2, 649.0, 634.0, 618.6, 507.5, 494.8 
5X Cu2+ ---- 1266.2, 1236.0, 866.0, 845.0, 824.2, 648.8, 634.0, 521.6, 507.1, 494.8 
5X Zn2+ 1267.3, 844.8, 633.6, 506.9 1236.5, 845.0, 824.5, 634.1, 618.9 
 
Figure 8. Cu2+ titration with 1 mM gad-1 in 75 mM HEPES and 100 mM NaCl 
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around 750 nm that needs to be investigated further. It is unclear what this peak is because it continues to 
grow even after 2 equivalents of Cu2+ was added.  
 It was also observed that the HXXXH site may not have a high affinity for binding to Zn2+. MS 
data showed low intensity Zn2+ bound peptide with 5X Zn2+ concentration (Figure 9). In addition to this, a 
competitive binding assay with zincon was performed to analyze whether the peptide had higher binding 
affinity for Zn2+ than zincon, which has a Kd of 12.6 μM.118 It was found that this was not the case, as 
titrating Zn2+ into peptide solution with equimolar amounts of zincon did not inhibit zincon binding 
(Figure 10). MIC data with gad-1 and added Zn2+ also yielded negative results showing that the activity of 
gad-1 with Zn2+ did not improve more than the WT. Again this shows that Zn2+ is potentially not bound 
by the peptide in a meaningful way. This data indicates that the Zn2+ can bind to gad-1 if there is a high 
concentration of metal ions, however, in vivo this may not be the case, as there was no increase in 
antimicrobial activity. The Irvings-Williams series explains that Cu2+ complexes have a greater stability 
than Zn2+ complexes, which can clarify why Cu2+ may preferably bind in the HXXXH position and 
potentiate activity in vivo.119  
 
Figure 9. MS data indicating that one Zn2+ ion binds to gad-1 with low affinity (A) gad-1 with no added  
Zn2+ (B) gad-1 with 5X Zn2+ 
 B
  A 
A 
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2.3 Secondary structure determination 
The secondary structure of the peptides were analyzed, along with apo-gad-1 and gad-1 in the 
presence of Cu2+ and Zn2+ ions, using CD spectroscopy. Figure 11 shows the CD spectra for the peptides 
in H2O and in a mixture of TFE and H2O. In H2O, all of the peptides display a disordered structure 
indicated by the minima at ~200 nm and the maxima at ~190 nm. The peptides in the presence of 50% 
TFE, a membrane mimetic solvent, exhibit double minima at 222 and 208 nm with maxima at ~195 nm; 
therefore, an α-helical conformation is induced in the presence of a membrane mimetic solvent. This is 
consistent with existing data on gad-1 that reported an α-helical structure in membrane mimetic solvent 
based on CD and NMR spectroscopy experiments.113 The switch from a disordered to an α-helical 
structure in the presence of membranes is consistent with other known AMPs such as magainin 2.17 The 
degree of helicity was calculated for each peptide using equation 2. Table 4 shows that H4A and H21A  
 
Figure 10. Competitive Zn2+ titration with zincon and gad-1 
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Figure 11. CD data (A) peptides in H2O (B) peptides in 50% TFE solution  
A 
B 
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had the lowest degree of helicity followed by gad-1. H3A, H11A, and H17A were the most helical 
structures. The degree of helicity of gad-1 does not match previous data from Booth et al. who reported 
that gad-1 was 100% helical in the presence of 50% TFE at pH 7.113 Based on the helical wheel diagram, 
some of these changes in helicity are unexpected. For example, substitution of H21 should not result in a 
large change when compared to the WT peptide because it is at the end of the sequence. Additionally, the 
substitution of H3, H4, and H17 were expected to yield higher helicity due to the fact that these residues 
are surrounded by hydrophobic residues such as F1, W8, V13, and I20. Consequently, the CD data was 
collected five times and each time resulted in the same trends in helicity of the peptides.  
The secondary structure and helicity of apo-gad-1 and gad-1 in the presence of a membrane 
mimetic solvent and metal ions was also investigated (Table 5). Our group has previously shown that 
there is not a large change in the CD spectrum or helicity of a peptide when they are metal bound.36 
Figure 12 shows the same trend with gad-1, where in the presence of both Cu2+ and Zn2+ at varied 
concentrations, there was not a large difference in the spectra or the helicity of the peptide. Overall, the 
secondary structure of gad-1 is consistent with previously collected data, indicating it forms an α-helix in 
the presence of TFE.  
 
 
 
 
Table 4: Summary of percent helicity in 50:50 
TFE:H2O 
Peptide Percent Helicity 
Gad-1 42.72 
H3A 45.93 
H4A 18.90 
H11A 57.14 
H17A 51.33 
H21A 19.54 
Table 5: Summary of percent helicity in 50:50 
TFE:H2O 
Peptide Percent Helicity 
Gad-1 42.72 
Gad-1 with 2X Cu2+ 31.22 
Gad-1 with 5X Cu2+ 33.45 
Gad-1 with 5X Zn2+ 39.10 
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Figure 12. (A) CD data of gad-1 with added Cu2+ (B) gad-1 with added Zn2+ 
Portelinha 37 
 
 
2.4 Antimicrobial activity 
The antimicrobial activity of gad-1 is summarized in Tables 6 and 7. First gad-1 and mutants 
were tested on the G(-) fish pathogens V. harveyi and A. hydrophila. Gad-1 showed modest activity 
against both pathogens, while the mutants were less effective. The MIC with A. hydrophila showed that 
H3 and H17 are essential to the activity because when they were substituted the activity of the peptide 
was abolished. The MIC of H11A and H17A was larger than 128 μM indicating clear importance of H11 
and H17 in the fish’s natural immunity against Aeromonas spp. Vibrio spp. also showed an overall higher 
MIC with the mutants, particularly in the absence of H4, which indicates some importance of this H 
against natural pathogens.  
 
 
 
 
 
 
 
 
 
 
 
Once the potency was proven in fish pathogens, E. coli, a model G(-) bacteria, was tested. Gad-1 
against E. coli exhibited high levels of activity with an MIC of 2 µM. H4A and H21A had essentially the 
same activity as gad-1, while H17A and H3A were observed to be less active, potentially due to the fact 
Table 6: Summary of MIC values (μM) for gad-1 and mutants (* denotes 
only two trials) 
Peptide E. coli E.coli with 
TETA 
 V. harveyi V. harveyi 
with TETA 
A. hydrophila 
Gad-1 2 16 8 16 16 
H3A 16 16 32 128 >128 
H4A 2 16 32 32 16 
H11A 8 16 *64 -- *>128 
H17A 8 16 16 *>64 >128 
H21A 4 16 16 16 16 
Table 7: Summary of MBC values (μM) for gad-1 and mutants (* denotes 
only two trials) 
Peptide E. coli E.coli with 
TETA 
 V. harveyi V. harveyi 
with TETA 
A. hydrophila 
Gad-1 2 16 16 16 16 
H3A 16 32 32 128 -- 
H4A 2 32 32 32 16 
H11A 8 16 *64 -- -- 
H17A 8 32 32 -- -- 
H21A 4 16 32 32 16 
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that these are the two predicted Cu2+ binding moieties. The MIC with TETA, an extracellular Cu2+ 
chelator, were also done to show that the low MIC of gad-1 is due to the Cu2+ bound state. WT gad-1 and 
all the mutants had an MIC of 16 µM, exactly the MIC of H3A alone with no TETA, indicating that the 
Cu2+ bound in the third position is essential for the antimicrobial activity of gad-1.  
TKK data using E. coli with 4 µM peptide showed that gad-1, H4A and H11A had similar killing 
abilities and were bactericidal at this concentration (Figure 13). H3A, H17A, and H21A mildly inhibited 
growth and were bacteriostatic at 4 µM, which is sub-MIC for all three mutants. H4A and gad-1 were  
 
both above MIC concentrations, while H21A is at MIC concentration, again reinforcing the fact that the 
H4 substitution does not seem to affect the activity of gad-1 against E. coli. This data indicates that H3, 
H17, and H21 are essential for the bactericidal activity of the peptide.  
 
Figure 13. TKK data at 4 μM peptide concentration showing that gad-1, H4A, and H11A are bactericidal  
at 4 μM, while the other mutants are bacteriostatic 
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2.5 Mechanism of action 
Multiple experiments were conducted to elucidate the mechanism of gad-1 and the potential role 
of H. First, a β-galactosidase assay was performed to see if the pores can leach β-galactosidase  
 
Table 8: Summary of β-galactosidase 
leakage 
Peptide Percent Leakage 
Gad-1 51.72 
H3A 51.38 
H4A 45.47 
H11A 38.15 
H17A 39.67 
H21A 34.18 
 
 
 
Figure 14. β-galactosidase data indicating leakage of cellular contents and percent leakage as compared  
to Triton X-100 
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out of the cell were being made. It was exhibited that at 2 µM concentration gad-1 and all of the mutants 
were similarly able to create pores in the cell membrane (Figure 14). In comparison to Triton X-100, the 
peptides had about 50% the absorbance which is good considering the low concentration that was being 
used (Table 8). This confirms that at least part of the lethality of gad-1 is modulated by pore formation. 
The ability to bore holes in the membrane is modulated in part by the amphipathicity of the peptide, 
therefore a one AA substitution should not alter the pore forming ability of the peptide drastically.   
The multi-hit nature of AMPs led to the testing of another probable mechanism of gad-1, which 
was hypothesized to be lipid peroxidation due to the ROS formation when the Cu-ATCUN complex is 
formed. It was shown that ixosin with an H3A mutation was significantly slower than WT ixosin at 
causing lipid peroxidation and after one hour peroxidized less than 50% of the WT peptide.48 It is 
postulated that gad-1 will have similar activity due to the presence of the ATCUN motif. Using a standard 
assay, with ixosin as a positive control, apo-gad-1 and bound-gad-1 were analyzed for quantity of lipid 
 
Figure 15. Lipid peroxidation of E. coli MWF1 with and without added Cu2+ where * is p>0.05 and ** is 
p>0.01 
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peroxidation with the mutants to elucidate which H residues may be necessary for enhanced lipid 
peroxidation. Apo-gad-1 and the mutants, with the exception of H11A, were all seen to peroxidize lipids 
to some extent (Figure 15), however, when 1 equivalent of Cu2+, was added the amount of lipid 
peroxidation increased significantly for gad-1 and H4A, while the difference between the H3A, H17A, 
and H21A with and without metal ions was not found to be significant. Cu2+ alone did not elicit any 
notable peroxidation when tested at 8 and 16 μM, indicating that if the Cu2+ was not able to bind the 
peptide it would not have significantly changed the amount of lipid peroxidation. This result confirms the 
importance of the ATCUN motif to modulate higher activity of gad-1. It also confirms that there is little 
to no change in oxidizing activity when H4 is substituted. H17A and H21A did not exhibit a statistically 
significant change with added Cu2+, which is interesting because this is where the second Cu2+ binding 
site may be located. It may be possible that this second binding site is also producing some ROS to 
contribute to antimicrobial activity.  
2.6 Toxicity 
Hemolysis on human erythrocytes was tested to examine if the peptide was selective for bacterial 
membranes and whether it may be used as a therapeutic agent in the future. All mutants were ~100% 
hemolytic at 4 µM, while gad-1 was about 50% hemolytic at its MIC of 2 µM (Figure 16). A previous 
work showed that the toxicity to cod erythrocytes were very low, although they only tested the hemolysis 
at up to 2 µM.28 McDonald et al. reported that gad-1 reached 100% hemolysis at 100 µM.113 The 
difference in data for the WT peptide can be explained by the method used. The buffer that was used was 
slightly different however, the bigger issue is the wavelength at which the plate was read. The Booth 
group used 541 nm to analyze the amount of hemoglobin while 414 nm was used in the current assay. 
Hemoglobin has two peaks that are both around these wavelengths, however, the peak at ~400 nm is 
much more intense, which could be a potential reason as to why the data differs.120  
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2.7 Discussion 
Based on the evidence presented here, gad-1 seems to utilize Cu2+ to potentiate activity against E. 
coli and the mechanism of gad-1 is membrane disruption, coupled with lipid peroxidation. The metal 
binding ability of gad-1 was tested with Cu2+ and Zn2+, demonstrating that Cu2+ has two potential binding 
sites, while Zn2+ did not bind at an observable amount. In addition to this, when Zn2+ was preincubated 
with gad-1 and an MIC was completed, it was seen not to increase or decrease the activity of the peptide, 
demonstrating that Zn2+ likely does not have a role in the activity of gad-1.  
The secondary structure of gad-1 and the mutants were determined to be disordered in water and 
α-helical in the presence of TFE. The percent helicity varied up to 38% between mutants with H4A being 
the least helical and H11A being the most helical. Apo-gad-1 and gad-1 in the presence of metal ions 
showed little to no change in the CD spectra or helicity of the peptide, consistent with previous reports.  
 
Figure 16. Hemolysis of gad-1 and mutants tested against human erythrocytes 
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The CD data showed that if gad-1 is binding metal it does not further stabilize the helix or increase the 
helicity of the peptide.  
The α-helical nature of the peptide coincides with the high activity of the peptide against E. coli. 
Similar to other α-helical peptides, the MIC of gad-1 was in the low μM range. The MIC of the mutants 
varied, with the largest change being the H3A substitution which had an 8-fold higher MIC value.  This 
change is substantial because of the importance of the ATCUN motif for the activity of other peptides that 
have been reported and indicates the importance of H3. H4 had the same MIC as gad-1, while H21A was 
2-fold higher. H17A and H11A both had 4-fold increases in MIC compared to gad-1. Interestingly, H21A 
and H17A could potentially be the second binding site of the peptide indicating importance of both of 
these residues in the antimicrobial and metal binding activity. When TETA, a Cu2+ selective extracellular 
chelator was added, the MIC of all mutants were equal to H3A, demonstrating that the activity of the 
peptide is partially dependent on H3 and Cu2+ binding. Other G(-) bacteria that are natural fish pathogens 
were analyzed as well, V. harveyi and A. hydrophila. Gad-1 showed activity against both pathogens. 
There was an inhibition of activity with all mutations, indicating that the H residues are important to the 
natural immunity of G. morhua, specifically H17 and H3, which had obliterated activity for both 
pathogens when compared to gad-1. Overall, the importance of residues H3 and H17, as well as Cu2+ 
binding was exemplified.  
The mechanism of action was elucidated and determined to be the combination of pore formation 
and lipid peroxidation. A β-galactosidase assay was used to show that the library of mutants was able to 
bore holes in the membrane at a concentration on 2 μM. The efficiency of pore formation was ~50% 
compared to Triton X-100 indicating high lytic activity. Another assay to confirm and expand upon the 
membrane activity was a lipid peroxidation assay, which has previously been shown to be a mode of 
action in ATCUN containing peptides. Apo-gad-1 and Cu2+ bound-gad-1 were significantly different from 
each other, where the bound-gad-1 had more lipid peroxidation activity due to ROS formation at the 
membrane interface. H4A showed a similar trend when bound to Cu2+, reinforcing that H4 may not be 
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significant for the antimicrobial activity of gad-1 against E. coli. Interestingly, the residues that are 
implicated in metal binding, H3A, H17A, and H21A, did not significantly change the amount of lipid 
peroxidation in the presence of Cu2+, again reinforcing the importance of these residues to the activity of 
gad-1.  
The toxicity of the peptides against human erythrocytes was also analyzed to determine whether 
gad-1 may be utilized as a potential therapeutic agent.  Previous reports have shown that gad-1 is not 
hemolytic towards cod erythrocytes but are partially hemolytic to human erythrocytes.28,113 Gad-1 and 
mutants were shown to be ~100% hemolytic at 4 μM. The hemolytic activity of gad-1 reported here 
differed from previous data, likely due to the method of data collection. Unfortunately, the hemolytic 
activity overlapped with the MIC of gad-1 making it unlikely as a therapeutic agent for humans, however, 
the potential for using gad-1 as an antimicrobial agent at fish farms is still an avenue of research to 
consider. Previously, transgenic plants or fish that express AMPs have been created and gad-1 may be 
utilized in fish farms to prevent disease.115,116  
2.8 Conclusions 
Gad-1, an AMP from the piscidin family, showed potent activity against E. coli and fish 
pathogens, demonstrating its importance in the natural defense of G. morhua. The mechanism of action of 
gad-1 was determined to be pore formation coupled with lipid peroxidation. The conservation of H 
residues in the piscidin family occurs at H3, H4, H11, and H17, which are all present in the sequence of 
gad-1 in addition to H21. The role of each H residue in the activity of gad-1 and the metal binding ability 
was investigated here. It was shown that H3 is exceedingly important to the activity of gad-1 due to the 
inclusion of this residue in the ATCUN motif. The presence of the ATCUN motif was shown to 
potentiate activity by increasing the ROS formation and thereby increasing the lipid peroxidation and 
potency of gad-1. Although it was found that H17 and H21 bind Zn2+ with low affinity, they are also 
important residues for Cu2+ as it is postulated that they are involved in a second Cu2+ binding site. H17 
may be crucial to the activity in nature as the activity was abolished when tested against fish pathogens. 
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H4 did not seem to contribute to the antimicrobial activity of gad-1 with E. coli and only slightly with the 
fish pathogens. Due to the high sequence conservation of the H in the piscidin family, it is probable that 
the role may be similar to other piscidins. Therefore, H4 in gad-1 may be similar to TP4 in that H4 may 
be important for antifungal activity rather than antibacterial activity.87 H11 and H21 were of interest 
because both residues reside outside of the helical region.113 Unfortunately, a full set of data for H11A 
was not collected, due to lack of available peptide. It was shown to be somewhat important but without 
more data no meaningful conclusions about this substitution can be made at this time. H21 was shown to 
have some impact on the MIC of gad-1 and may be important in binding to Cu2+. There was no 
observable change in lipid peroxidation in the presence of Cu2+ for either H17A or H21A, indicating that 
ROS may also be produced at the second binding site.  
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CHAPTER 3 
Experimental methods 
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*Any water used was obtained from a Barnstead NANOpure Diamond filtration system with a 0.2 mm 
pore size filter. Peptides were purchased from Atlantic peptides. All chemicals are from Sigma Aldrich 
unless otherwise specified.  
3.1 Cu2+ titration 
A 1 mL solution of 1 mM peptide was diluted in 75 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) and 100 mM NaCl (JT Baker) pH 7.40 buffer. Twenty mM 
CuSO4 (JT Baker) stock in H2O was used and the peptide solution was titrated at intervals of 0.2 
equivalents of Cu2+ until 3 equivalents was reached. After Cu2+ addition, the solution was mixed and 
equilibrated for two minutes before each scan. The absorbance of the sample was read from 300-800 nm 
using a Cary 50 Scan UV-Visible spectrophotometer (Varian). The titration was also repeated in water.  
3.2 Zincon titration 
A ZnSO4 solution was prepared in H2O at a concentration of 10 mM. A 1 mL solution of peptide 
at 20 µM was added to 1 mL equimolar zincon (Alfa Aesar). The peptide was diluted using 75 mM 
HEPES with 100 mM NaCl at a pH of 7.40. A 1 µL aliquot of 2 mM Zn2+ was added and the solution was 
mixed and left to equilibrate for two minutes. The absorbance was then read from 300-800 nm. In total 4 
equivalents of Zn2+ was added to the cuvette.  
3.3 Electrospray ionization mass spectrometry (ESI-MS) 
A 10 mM Cu2+ stock was prepared with CuSO4 in H2O. Twenty µL of 50 μM peptide was mixed 
with Cu2+ in different ratios (1X, 2X, 3X, and 5X) in H2O and incubated for 45-60 minutes. Zn2+ was 
similarly tested with 5X Zn2+ from Zn(C2H3O2)2 and 5 mM NH4C2H3O2 buffer was used instead of H2O. 
Zn2+ was added to the peptide and the sample was also incubated for 45-60 minutes before injection. The 
samples were run on a 4000-Q TRAP LC/MS/MS system by Applied Biosystems. 
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3.4 CD measurements 
The peptides were diluted to 50 µM in 300 µL of H2O or a 50:50 H2O:TFE mixture. They were 
run on the Applied Photophysics ℼ*-18C instrument in a 0.1-cm quartz cuvette at room temperature. Each 
sample was run with two replicates at 1.0 nm intervals from 250-190 nm. The bandwidth was 3 mm. Data 
were analyzed using equation 1 to calculate the mean residue ellipticity (MRE, degree*cm2/dmol) where l 
is pathlength in cm, c is concentration in M, and n is the number of residues.121 When metal ions were 
added to the peptide samples, they were incubated for 45 to 60 minutes before analysis. The 
concentrations of the peptides were determined immediately before making the dilutions to ensure that a 
50 μM concentration was used. Percent helicity was calculated from equation 2.122  
 
 
 
3.5 MIC and MBC measurements 
All MIC assays utilized sterile 96-well polypropylene round bottom plates (Grenier). A 105 µL 
aliquot of the peptide, at 256 µM, was prepared in Mueller Hinton Broth (MHB) media. In column one of 
the plate, 100 µL of the peptide solution was plated. Then a 2-fold serial dilution was done until column 
10. A sterility control contained 100 µL of MHB and a positive control consisted of 50 µL MHB and a 50 
µL aliquot of bacteria. A 10 mL MHB culture was inoculated with two to five colonies of E. coli 
MG1655 and incubated at 37˚C for four hours (midlog phase OD600~0.4). A 50 µL aliquot of the 
inoculum was added to all wells except the sterility control, making the final concentration of cells 5X105. 
Plates were examined after 18-20 hours. The MIC was determined based on visual turbidity, with the 
MIC being the lowest concentration where growth did not occur. The minimal bactericidal concentration 
(MBC) was subsequently determined by plating 10 µL of inoculum to a Luria Broth (LB) plate at MIC 
concentration and 2X the MIC concentration. The plate was incubated for 18-20 hours at 37˚C and colony 
Equation 2. % helicity=−100 ∗
𝜃222 𝑛𝑚+3000
33000
 
   Equation 1. [θ]=
θ
10lcn
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growth was observed. MIC and MBC values are reported as the mean and the data is representative of at 
least three trials. The MIC in the presence of triethylenetetramine (TETA) was run with 400 μM TETA 
that was added to the media to ensure that there was no labile Cu2+ ions. When testing Vibrio harveyi and 
Aeromonas hydrophila LB with 2% and 1% NaCl, respectively, as these are optimal growth conditions 
for these pathogens. The plates were grown for three days at room temperature and MBC plates were also 
grown for three days at room temperature.  
3.6 Time kill kinetics (TKK) measurements 
Two to five E. coli MG1655 colonies were inoculated in a 10 mL MHB culture and incubated at 
37˚C for four hours. The bacteria were diluted in MHB media to 1X106 cells. Peptide solutions at a 
concentration of 8 µM were prepared in MHB media in a volume of 350 µL. The peptide solutions were 
added to 350 µL of diluted E. coli in a 5 mL plastic tube. The positive control consisted of 350 µL of 
MHB inoculated with 350 µL of E. coli. The samples were incubated at 37˚C with shaking at 234 rpm.  
At each time point the samples were diluted appropriately (up to 10,000 fold) into MHB and 100 µL was 
plated and spread on LB plates immediately after adding the bacteria at zero-hour and then at one-hour, 
two-hour, and four-hour time points. The plates were incubated for 18-20 hours at 37˚C and the colonies 
were counted to quantify the inhibition of growth. The data presented is representative of three trials.  
3.7 β-galactosidase leakage assay  
E. coli, transformed with the plasmid pUC19, was grown to an OD600 of 0.4 to 0.6. The cells were 
induced by 1 mM isopropyl β-D-1thiogalactopyranoside (IPTG) for one hour and then washed with 5 mL 
of phosphate buffered saline (PBS) 3X for ten minutes. The cells were resuspended to a culture volume of 
10 mL of MHB. A 75 µL aliquot of bacteria was then incubated with 75 µL of peptide, diluted in PBS, at 
a final concentration of 2 µM. The samples were incubated at 37˚C for one hour. The tubes were 
centrifuged for ten minutes at 4˚C. A 100 µL aliquot of supernatant was added to 50 µL of 8 mg/mL o-
nitrophenyl-β-D-galactopyranoside (ONPG, freshly prepared) in PBS. The 150 µL was then plated in a 
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96-well plate and read every five minutes for one hour at 405 nm. The data is represented as a percentage 
where 0.1% Triton X-100 is 100%. The negative control was PBS mixed with ONPG and this was 
subtracted from all values before calculating the percentages. Data from the one-hour time point was used 
and a total of three to four trials were done to confirm the activity.   
3.8 Lipid peroxidation assay  
MWF1, fabR::kan recD::Tn10, an E. coli strain with a high number of unsaturations in the 
bilayer, was grown for four hours and was washed 3X with 20 mM HEPES and 100 mM NaCl buffer at 
pH 7.4. The cells were resuspended in 10 mL of buffer and diluted to 2X107 cells. Peptide solutions were 
prepared in buffer at 2X the final concentration (4 µM). An aliquot of 50 µL of diluted bacteria and 50 µL 
of peptide solution were added and incubated for two hours at 37˚C. Once the treatment concluded, 100 
µL of trichloroacetic acid (1% w/v) was added to each sample, followed by 800 µL of colorimetric 
reagent (106 mg thiobarbatuic acid, 10 mL of 0.7 M NaOH, and 10 mL of 20% acetic acid). The samples 
were vortexed and then added to a dry heat block at 97˚C for 60 minutes. The samples were put in a -20˚C 
freezer for 10-20 minutes to cool to room temperature. The samples were centrifuged for ten minutes at 
4˚C and then a 200 µL aliquot was added to a 96-well black plate in duplicate. The fluorescence was 
recorded at 530 nm excitation and 550 nm emission and relative fluorescence intensity is reported. 
Standards (0-5 µM) were run using 1,1,3,3-tetramethoxypropane, diluted in buffer. The data is 
representative of four to five trials.  
3.9 Hemolysis assay 
A 150 µL solution of 16 µM peptide was prepared and serially diluted into PBS for a 
concentration range of 8 to 0.5 µM. In a 15 mL sterile falcon tube, 1 mL of human erythrocytes were 
added to 9 mL of PBS. This mixture was centrifuged for ten minutes at 4˚C and the supernatant was 
removed until the supernatant was light pink. From the washed erythrocytes a 0.8% (v/v) solution in PBS 
was prepared. A 75 µL aliquot of the diluted erythrocytes was added to 75 µL of serially diluted peptide 
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and was incubated for one hour at 37˚C. The tubes were then centrifuged for five minutes and 100 µL of 
supernatant was added to a 96-well polypropylene plate. This was read on a standard plate reader at 414 
nm. PBS was used as a negative control and 1% Triton X-100 was used as the positive control. The 
controls were run in duplicate for each of the three trials. Equation 3 was used to calculate the percent 
hemolysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Equation 3.  % ℎ𝑒𝑚𝑜𝑙𝑦𝑠𝑖𝑠 =
APeptide−APBS
ATriton−APBS
∗ 100% 
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